IMUX · Immunic, Inc.
Market Cap
$127.51M
Shares
13.64M
Volume · Oct 6
347.89K
Avg daily vol (3M)
273.59K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.82
Open$8.13
Day$7.77–8.17
52W close$5.10–16.90
Avg vol 30d399K
Short int1.8M · 13.2% float · 5.0d
Short vol33%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
call held Nov 7, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
13.2%
Latest settlement · 5.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−40%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−30%
trailing
YTD return
+46%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-27% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.15% of float · ▲ +20.4% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-86.0M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
10.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2023
Cash, Cash Equivalents and Investments (expected to fund operati
· into the fourth quarter of 2024
$77.3M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−40%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow
Distributing
-27% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.15% of float · ▲ +20.4% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $8 · 23%
Range high $17
vs 200-day avg -31%
vs 50-day avg -40%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMUX
this stock
Immunic, Inc.
|
$127.51M | — | — | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMUX | -12.2% | -38.6% | -29.6% | -15.9% | +46.4% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -14.2% | -40.3% | -40.9% | -18.1% | +32.2% |